AURO-AZITHROMYCIN 200 MG / 5 ML
AZITHROMYCIN (AZITHROMYCIN DIHYDRATE) : 200 MG / 5 ML · DIN 02482371 · AURO PHARMA INC
Health Canada status: MARKETED
What is AURO-AZITHROMYCIN?
AURO-AZITHROMYCIN 200 MG / 5 ML contains AZITHROMYCIN (AZITHROMYCIN DIHYDRATE) : 200 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 02482371, held by AURO PHARMA INC, supplied as POWDER FOR SUSPENSION for ORAL administration. Health Canada currently lists it as marketed, status dated 30-Oct-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AURO-AZITHROMYCIN used for?
Treatment of mild to moderate infections: pharyngitis/tonsillitis, AECB, community-acquired pneumonia, skin infections, GU tract infections (chancroid, urethritis, cervicitis), and MAC prevention.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02482371 |
|---|---|
| Brand name | AURO-AZITHROMYCIN |
| Generic / active ingredient | AZITHROMYCIN (AZITHROMYCIN DIHYDRATE) : 200 MG / 5 ML |
| Manufacturer | AURO PHARMA INC |
| Strength | 200 MG / 5 ML |
| Dosage form | POWDER FOR SUSPENSION |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01FA10 AZITHROMYCIN |
| AHFS class | 08:12.12.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 30-Oct-2019 |
| Original market date | 2019-10-30 00:00:00 |
How is it administered?
Adults: 500mg-2g total dose depending on indication. Pediatrics: 30-60mg/kg total dose depending on indication. Can be taken with or without food. Shake well before use.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Keep tightly closed. (Specific temperature range not provided in snippet, refers to 'Storage, Stability and Disposal' section).
How is it supplied?
Heavy Weight HDPE bottles: 15 mL (for 300mg/600mg), 22.5 mL (for 900mg), and 37.5 mL (for 1500mg).
Contraindications
History of cholestatic jaundice/hepatic dysfunction with prior azithromycin use; hypersensitivity to azithromycin, erythromycin, any macrolide/ketolide, or formulation ingredients.
Warnings and precautions
Risk of QT prolongation and torsade de pointes; Clostridioides difficile associated disease (CDAD); caution in patients with saccharide intolerance (contains sucrose).
Is AZITHROMYCIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by EUGIA PHARMA INC., last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01FA10 AZITHROMYCIN. 23 of 84 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-AZITHROMYCIN | 250 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02480700 |
| APO-AZITHROMYCIN Z | 250 MG | TABLET | APOTEX INC | MARKETED | DIN 02415542 |
| AURO-AZITHROMYCIN | 100 MG / 5 ML | POWDER FOR SUSPENSION | AURO PHARMA INC | MARKETED | DIN 02482363 |
| AZITHROMYCIN | 250 MG | TABLET | 10445517 CANADA INC / NORTH PHARMACEUTICALS / DAC PHARMACEUTICALS | MARKETED | DIN 02545969 |
| AZITHROMYCIN | 250 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02442434 |
| AZITHROMYCIN | 250 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02330881 |
| AZITHROMYCIN FOR INJECTION | 500 MG | POWDER FOR SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02523825 |
| AZITHROMYCIN FOR INJECTION | 500 MG | POWDER FOR SOLUTION | GENERIC MEDICAL PARTNERS INC | MARKETED | DIN 02524449 |
| AZITHROMYCIN FOR INJECTION USP | 500 MG | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02483890 |
| AZITHROMYCIN FOR INJECTION, USP | 500 MG | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | DIN 02465604 |
Who else supplies AZITHROMYCIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. AZITHROMYCIN appears in 4088 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.